Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Share-based Compensation (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Share-based Compensation data on record, last reported at $1.9 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 85.26% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $5.1 million, down 13.51%, while the annual FY2024 figure was $4.8 million, 48.49% down from the prior year.
  • Share-based Compensation reached $1.9 million in Q3 2025 per TNXP's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.8 million in Q1 2023 and bottomed at $882000.0 in Q1 2025.
  • Average Share-based Compensation over 3 years is $1.7 million, with a median of $1.7 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: plummeted 56.13% in 2024, then soared 85.26% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $2.0 million in 2023, then crashed by 56.13% to $894000.0 in 2024, then surged by 115.1% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $1.9 million in Q3 2025, $1.4 million in Q2 2025, and $882000.0 in Q1 2025.